Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2025-03-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 15th meeting of the 8th Board of Directors of 华兰生物工程股份有限公司. It includes approvals of various reports such as the 2024 Annual Report, 2024 Financial Statements, 2024 Audit Report, profit distribution plan, changes in accounting policies, internal control self-assessment, ESG report, and other governance matters. The document references the 2024 Annual Report and other reports being published on the official disclosure website but does not contain the full annual report or financial statements itself. It is a formal board meeting resolution announcement that summarizes the board's decisions and approvals, which will be submitted to the 2024 Annual General Meeting for approval. This type of document is best classified as Board/Management Information (MANG) because it reports on board meeting decisions and management reports rather than being the full annual report or standalone audit report. The document length (5299 characters) and content support this classification rather than a full Annual Report (10-K) or Audit Report (AR).
2025-03-28 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of a company, describing their duties, attendance at meetings, oversight activities, and opinions on company matters for the year 2024. It includes references to the annual report, quarterly reports, audit firm renewal, profit distribution, and governance activities. The content is a comprehensive management-related report focusing on the director's role and activities rather than financial statements or audit results alone. It is not a full annual report (10-K) or audit report (AR), nor is it a brief announcement or voting result. It fits best under Board/Management Information (MANG) as it details the independent director's annual duties and governance role.
2025-03-28 Chinese
华兰生物工程股份有限公司市值管理制度
Governance Information Classification · 95% confidence The document is titled '市值管理制度' (Market Value Management System) issued by the company's board of directors. It outlines the company's policies, principles, organizational responsibilities, and prohibited behaviors related to managing the company's market value and investor relations. It is a governance-related internal policy document rather than a financial report, earnings release, or announcement of voting results. It does not contain financial statements, audit information, or regulatory filings. It is not a presentation or a call transcript. The document is a formal governance policy issued by the board, focusing on internal rules and governance practices related to market value management. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3593 characters, which is not extremely short, and it is a full policy document, not an announcement of a report publication or a certification. Hence, CGR fits best with high confidence.
2025-03-28 Chinese
年度股东大会通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of 华兰生物工程股份有限公司, including the date, time, location, voting procedures, agenda items, and instructions for shareholders. It includes information about proposals to be voted on, registration details, and proxy forms. The document does not contain financial statements or detailed financial performance data, but rather serves as an official notification and procedural guide for the upcoming AGM. Therefore, it fits the category of AGM Information (AGM-R). The document length (9039 characters) and content confirm it is a full notice rather than a brief announcement or a report publication announcement.
2025-03-28 Chinese
华兰生物工程股份有限公司舆情管理制度
Governance Information Classification · 95% confidence The document is titled '舆情管理制度' which translates to 'Public Opinion Management System' or 'Crisis Communication Management Policy' for the company 华兰生物工程股份有限公司. It outlines internal policies and procedures for managing public opinion, media reports, and information that could affect the company's reputation and stock price. The content is a governance or internal control document rather than a financial report, earnings release, or regulatory filing. It does not contain financial data, audit information, voting results, or announcements related to capital or management changes. It is a policy document approved by the board, focusing on governance and communication protocols. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3172 characters, which is relatively short but contains substantive policy content, not just an announcement or certification, so it is not RPA or RNS.
2025-03-28 Chinese
关于董事长、实际控制人、部分董事、高级管理人员增持计划期限届满暨增持完成的公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding the completion of a share increase plan by the chairman, actual controller, some directors, and senior management of the company. It details the shareholding before and after the increase, the number of shares increased, the purpose of the increase, and compliance with relevant laws and regulations. There are no financial statements or detailed financial performance data. The document is primarily about insider share transactions and completion of a shareholding increase plan, which fits the category of Director's Dealing (DIRS). The document length is 4414 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the appropriate classification is DIRS with high confidence.
2025-01-08 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.